Calidi Biotherapeutics issues amended warrant for 17.4M shares at $0.23, subject to stockholder approval

Calidi Biotherapeutics, Inc.

Issued amended warrant to accredited investor for 17,391,304 unvested shares at $0.23 exercise price.
Exercise conditioned on stockholder approval; minimum vesting acquisition amount increased to $1M from $500K.
Vesting termination date extended from July 8, 2026 to September 30, 2026.
Private placement exempt under Section 4(a)(2) and Rule 506(b); shares not registered.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.95

Calidi Biotherapeutics, Inc. issued up to 17,391,304 (unvested) shares of common stock of warrant to an accredited investor (the "Holder") for exercise price of $0.23.

Security: warrant
Shares: up to 17,391,304 (unvested) shares of common stock
Purchaser: an accredited investor (the "Holder")
Consideration: exercise price of $0.23

Exact text from the filing

On May 28, 2026, Calidi Biotherapeutics, Inc. (the “Company”) issued an amended and restated warrant (the “Warrant”) to purchase up to 17,391,304 (unvested) shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”), with an exercise price of $0.23 to an accredited investor (the “Holder”) in a private placement transaction.

View on SEC.gov

Browse all equity issuances →

Calidi Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-026415

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.